Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

This study has been completed.
Information provided by (Responsible Party):
Dow Pharmaceutical Sciences Identifier:
First received: April 23, 2008
Last updated: February 16, 2012
Last verified: February 2012
The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.

Condition Intervention Phase
Acne Vulgaris
Drug: Low Strength IDP-107
Drug: High Strength IDP-107
Drug: Placebo Comparator
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris With Nodules

Resource links provided by NLM:

Further study details as provided by Dow Pharmaceutical Sciences:

Primary Outcome Measures:
  • Change from baseline in the number of inflammatory lesions [ Time Frame: 12 weeks ]
  • Improvement from baseline in global severity [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Change from baseline in the number of non-inflammatory lesions [ Time Frame: 12 weeks ]

Enrollment: 366
Study Start Date: January 2008
Study Completion Date: September 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Low Strength IDP-107
Once a day for 12 weeks
Experimental: 2 Drug: High Strength IDP-107
Once a day for 12 weeks
Placebo Comparator: 3 Drug: Placebo Comparator
Once a day for 12 weeks


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Presence of inflammatory and non-inflammatory lesions

Exclusion Criteria:

  • Dermatological conditions of the face that could interfere with clinical evaluations
  • Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00666900

  Show 25 Study Locations
Sponsors and Collaborators
Dow Pharmaceutical Sciences
  More Information

Responsible Party: Dow Pharmaceutical Sciences Identifier: NCT00666900     History of Changes
Other Study ID Numbers: DPSI-IDP-107-P2-01
Study First Received: April 23, 2008
Last Updated: February 16, 2012

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases processed this record on May 25, 2017